Study ID: Iverson Genetics WARFARIN

Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)


Participants in this study are being prescribed a blood thinner to prevent blood clots. . The blood thinner warfarin (Coumadin ®) is commonly prescribed for this purpose. Doctors have been prescribing warfarin for a long time and they have procedures to try to get to the correct dose as soon as possible. There is a bit of guessing in this procedure. Researchers who study warfarin’s affects have found that part of the difference in reaction to warfarin is due to the genes of the patient. That is, each person has inherited his or her ability to react to warfarin. There is a test that can be performed using a patient’s blood which determines two of the genes involved in their response to warfarin. If the doctor has information about a patient’s genes he can use that information to help determine the dose of warfarin. We want to find out if using the test results to figure out a patient’s dose will lead to fewer problems than the standard way of figuring out the dose.

Fargo Region
Principal Investigator:
Susan I Farkas


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list